These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 16096428)

  • 21. Clinical trials using irinotecan.
    Houghton PJ; Santana VM
    J Pediatr Hematol Oncol; 2002 Feb; 24(2):84-5. PubMed ID: 11990709
    [No Abstract]   [Full Text] [Related]  

  • 22. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.
    Takahashi N; Li W; Banerjee D; Guan Y; Wada-Takahashi Y; Brennan MF; Chou TC; Scotto KW; Bertino JR
    Cancer Res; 2002 Dec; 62(23):6909-15. PubMed ID: 12460906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis.
    Pencreach E; Guérin E; Nicolet C; Lelong-Rebel I; Voegeli AC; Oudet P; Larsen AK; Gaub MP; Guenot D
    Clin Cancer Res; 2009 Feb; 15(4):1297-307. PubMed ID: 19190131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Camptothecin analogues and vinblastine in the treatment of renal cell carcinoma: an in vivo study using a human orthotopic renal cancer xenograft.
    El-Galley R; Keane TE; Sun C
    Urol Oncol; 2003; 21(1):49-57. PubMed ID: 12684128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MGI 114: augmentation of antitumor activity when combined with topotecan.
    Weitman S; Barrera H; Moore R; Gonzalez C; Marty J; Hilsenbeck S; MacDonald JR; Waters SJ; Von Hoff D
    J Pediatr Hematol Oncol; 2000; 22(4):306-14. PubMed ID: 10959900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
    Pignochino Y; Capozzi F; D'Ambrosio L; Dell'Aglio C; Basiricò M; Canta M; Lorenzato A; Vignolo Lutati F; Aliberti S; Palesandro E; Boccone P; Galizia D; Miano S; Chiabotto G; Napione L; Gammaitoni L; Sangiolo D; Benassi MS; Pasini B; Chiorino G; Aglietta M; Grignani G
    Mol Cancer; 2017 Apr; 16(1):86. PubMed ID: 28454547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trabectedin and irinotecan combination regresses a cisplatinum-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model.
    Higuchi T; Miyake K; Oshiro H; Sugisawa N; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Biochem Biophys Res Commun; 2019 May; 513(2):326-331. PubMed ID: 30955860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
    Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
    Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group.
    Baruchel S; Pappo A; Krailo M; Baker KS; Wu B; Villaluna D; Lee-Scott M; Adamson PC; Blaney SM
    Eur J Cancer; 2012 Mar; 48(4):579-85. PubMed ID: 22088484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of combination treatment and influence of schedule with irinotecan and amrubicin in human lung carcinoma cells in vivo and in vitro.
    Shishido Y; Furuta T; Matsuzaki T; Nagata H; Hashimoto S
    Biol Pharm Bull; 2010; 33(7):1183-91. PubMed ID: 20606311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
    Ordóñez JL; Amaral AT; Carcaboso AM; Herrero-Martín D; del Carmen García-Macías M; Sevillano V; Alonso D; Pascual-Pasto G; San-Segundo L; Vila-Ubach M; Rodrigues T; Fraile S; Teodosio C; Mayo-Iscar A; Aracil M; Galmarini CM; Tirado OM; Mora J; de Álava E
    Oncotarget; 2015 Aug; 6(22):18875-90. PubMed ID: 26056084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.
    Shimoyama T; Koizumi F; Fukumoto H; Kiura K; Tanimoto M; Saijo N; Nishio K
    Lung Cancer; 2006 Jul; 53(1):13-21. PubMed ID: 16713012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
    Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trabectedin has promising antineoplastic activity in high-grade meningioma.
    Preusser M; Spiegl-Kreinecker S; Lötsch D; Wöhrer A; Schmook M; Dieckmann K; Saringer W; Marosi C; Berger W
    Cancer; 2012 Oct; 118(20):5038-49. PubMed ID: 22392434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
    Kim S; Prichard CN; Younes MN; Yazici YD; Jasser SA; Bekele BN; Myers JN
    Clin Cancer Res; 2006 Jan; 12(2):600-7. PubMed ID: 16428506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).
    Romano M; Frapolli R; Zangarini M; Bello E; Porcu L; Galmarini CM; García-Fernández LF; Cuevas C; Allavena P; Erba E; D'Incalci M
    Int J Cancer; 2013 Nov; 133(9):2024-33. PubMed ID: 23588839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
    Mans DR; Grivicich I; Peters GJ; Schwartsmann G
    Eur J Cancer; 1999 Dec; 35(13):1851-61. PubMed ID: 10674003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
    Britten CD; Hilsenbeck SG; Eckhardt SG; Marty J; Mangold G; MacDonald JR; Rowinsky EK; Von Hoff DD; Weitman S
    Cancer Res; 1999 Mar; 59(5):1049-53. PubMed ID: 10070962
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.